来那度胺与环磷酰胺治疗多发性骨髓瘤患者的效果比较  

Comparison of effects of Lenalidomide and Cyclophosphamide in treatment of patients with multiple myeloma

作　　者：段菲菲[1] DUAN Feifei(Department of Hematology of Anyang People’s Hospital,Anyang 455000 Henan,China)

机构地区：[1]安阳市人民医院血液内科,河南安阳455000

出　　处：《中国民康医学》2024年第18期138-140,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:比较来那度胺与环磷酰胺治疗多发性骨髓瘤患者的效果。方法:回顾性分析2019—2022年该院收治的112例多发性骨髓瘤患者的临床资料,根据治疗方法不同将其分为对照组(n=53)与研究组(n=59)。两组均给予硼替佐米、地塞米松治疗,在此基础上,对照组联合环磷酰胺治疗,研究组联合来那度胺治疗。比较两组临床疗效、不良反应发生率及治疗成本。结果:研究组高质量缓解率为62.71%(37/59),高于对照组的35.85%(19/53),差异有统计学意义(P<0.05);两组总缓解率比较,差异无统计学意义(P>0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);研究组总成本、成本-效果均高于对照组,差异有统计学意义(P<0.05)。结论:在硼替佐米、地塞米松治疗基础上采用来那度胺治疗多发性骨髓瘤患者可提高高质量缓解率的效果优于环磷酰胺治疗,但需增加治疗成本。Objective:To compare effects of Lenalidomide and Cyclophosphamide in treatment of patients with multiple myeloma.Methods:The clinical data of 112 patients with multiple myeloma admitted to the hospital from 2019 to 2022 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=53)and study group(n=59).Both groups were treated with Bortezomib and Dexamethasone.On this basis,the control group was treated with Cyclophosphamide,while the study group was treated with Lenalidomide capsules.The clinical efficacy,the incidence of adverse reactions,and the treatment cost were compared between the two groups.Results:The high-quality remission rate of the study group was 62.71%(37/59),which was higher than 35.85%(19/53)of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total remission rate between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The total cost and the ratio of total cost to effect of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:On the basis of Bortezomib and Dexamethasone treatment,Lenalidomide can improve the high-quality remission rate in patients with multiple myeloma,which is better than Cyclophosphamide treatment,but the treatment cost needs to be increased.

关 键 词：多发性骨髓瘤 环磷酰胺 来那度胺 硼替佐米 地塞米松 缓解率 治疗成本 

分 类 号：R733.3[医药卫生—肿瘤]